Navigation Links
Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
Date:8/8/2012

PHILADELPHIA and REHOVOT, Israel, Aug. 8, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. ("Rosetta") (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the closing of an underwritten public offering of 5,500,000 ordinary shares at an offering price of $5.00 per share. The gross proceeds to Rosetta were $27.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta.  In addition, Rosetta has granted the underwriter a 45-day option to purchase up to 825,000 additional ordinary shares to cover over-allotments, if any.

Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of future indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

A registration statement on Form F-1 relating to the shares was filed with the Securities and Exchange Commission (the "SEC") and was declared effective on August 2, 2012.
A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov.
Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.

This press release shall not constitute an offer to
'/>"/>

SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
2. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
5. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
6. First Plant Genomics Yield Technology Progresses
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
11. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Equity Research, Inc.,(Scimitar) issues a review of Neurobiological ... Treatments, Look at One Stroke,Drug at a Time; ... available at our website: http://www.scimitarequity.com ., ... in the business of acquiring and developing central ...
... Feb. 14 BiPar Sciences, Inc., a,privately held ... Huh, M.D., Ph.D., has been appointed,President and Chief ... on,March 3, 2008., Dr. Huh previously served ... Business Unit at Nektar Therapeutics, a drug development ...
... 14 GeoPharma, Inc. (Nasdaq:,GORX) announced record revenues ... than a 200% increase in sales sequentially, as ... month periods ending,December 31, 2007., "We are ... the,third quarter of our 2008 fiscal year; it ...
Cached Biology Technology:Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc. 2BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer 2GeoPharma Announces Record Revenues in Third Quarter Results 2GeoPharma Announces Record Revenues in Third Quarter Results 3GeoPharma Announces Record Revenues in Third Quarter Results 4GeoPharma Announces Record Revenues in Third Quarter Results 5GeoPharma Announces Record Revenues in Third Quarter Results 6
(Date:5/23/2013)... at Rollins School of Public Health at Emory ... of Technology, have received a $4 million grant ... at Emory University (Health and Exposome Research Center: ... exposome-based center grant awarded in the United States. ... the National Institute of Environmental Health Sciences (NIEHS) ...
(Date:5/23/2013)... Given the implications for the overall health, ... play a primary role in ensuring that all ... 60 minutes per day of vigorous or moderate-intensity ... Institute of Medicine. Recent estimates suggest that ... evidence-based guideline for promoting better health and development. ...
(Date:5/23/2013)... in treating cerebral palsy with autologous cord blood. Following ... year old boy had been in a persistent vegetative ... months after treatment with the cord blood containing stem ... the child learned to speak simple sentences and to ... study, dispel the long-held doubts about the effectiveness of ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... VALLEY, Pa., June 1, 2009 Olympus America Inc. ... NIR, a biliary metallic stent designed with exceptional anatomic ... NIRflex cell design provides a physician support and flexibility; ... pancreatic, liver and bile duct cancers. ...
... how different species are likely to respond to climate ... a species and the interactions between species, in the ... of BioScience , by Eric Post of Pennsylvania ... can be avoided. Their approach, which relies on multi-stage ...
... our cells possess an internal clock, a group of genes ... a day. A large number of circadian genes are expressed ... be precisely regulated over the course of the day. A ... Research Frontiers in Genetics, based at the University of Geneva, ...
Cached Biology News:MicroRNAs grease the cell's circadian clockwork 2
... quick and easy operation of a wide ... The software is fully secure and ... Part 11 regulations, and compatible with user-created ... versatility enables use in high-level research and ...
... We can introduce random mutations to the ... be then cloned into a vector of choice ... Mutation frequency can be set to a ... Number of clones 106-108. Mutations can be ...
... The Freedom EVOlyzer is Tecans new Enzyme-Linked ... microplate processing. Freedom EVOlyzer is a dedicated ... state-of-the art reader, washer and incubation units ... The Freedom EVOlyzer is available in three ...
... The Digital Clamp One can operate as ... as a Conductance (Dynamic) Clamp in electrophysiology research ... as good as conventional analog equipment. This ... advances in the capabilities of Digital Signal Processing ...
Biology Products: